David J Blacker
David Blacker AM, MBBS, FRACP
David is a long standing member of the SSA and has been active in establishing stroke services in Western Australia. He has been involved with stroke research at many levels, from basic science, phase 1,2 and 3 clinical trials, in acute and preventive treatments and rehabilitation. He has a long association with the stroke research laboratory at the Perron Institute, where he has also been the Medical Director since 2015.
Along with Graeme Hankey, he leads the Phase II study of ARG-007 in acute iscemic stroke (SEANCON).
Abstracts this author is presenting:
-
A Phase 1, double-blind, randomised, placebo-controlled, sequential-group study to assess the safety, tolerability and pharmacokinetics of single ascending doses of ARG-007 in healthy participants.
—
Session 7.3 - Novel Approaches to Acute Stroke Care
-
Phase II, double-blinded, randomised, placebo-controlled study to determine the safety, preliminary efficacy and pharmacokinetics of ARG-007 in acute ischaemic stroke patients (SEANCON)
—
Lunch and Poster Session 1: Stroke Rehabilitation and Recovery, Quality Improvement, Stroke Service Development and Implementation Research, Co-designed Research & Discovery Science
